Home ETF List About

ETF Holdings Breakdown of AXSM

Stock NameAxsome Therapeutics Inc
TickerAXSM(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS05464T1043
LEI549300EXGR0XLRJEIB95

AXSM institutional holdings

The following institutional investment holdings of AXSM have been identified

Date ETF ISIN/Name Num Shares Book value
2025-10-17 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 8,064USD 1,031,708
2025-10-17 IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc)) 46,980USD 6,010,621
2025-10-17 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 31,622USD 4,045,719
2025-10-17 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 31,622USD 4,045,719
2025-10-17 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 25,937USD 3,318,380
2025-10-17 IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc)) 185USD 23,669
Total =144,410 USD 18,475,816
Book value of shares is calculated on the adjusted close price of each day (row).

News associated with AXSM

Roger Jeffs Sells 13,464 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock
Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report) Director Roger Jeffs sold 13,464 shares of the business’s stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $123.68, for a total value of $1,665,227.52. Following the completion of the sale, the director owned 57,510 shares in […] - 2025-09-04 05:23:00
Deutsche Bank AG Lowers Stock Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)
Deutsche Bank AG reduced its stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 21.2% during the first quarter, Holdings Channel reports. The institutional investor owned 94,980 shares of the company’s stock after selling 25,567 shares during the period. Deutsche Bank AG’s holdings in Axsome Therapeutics were worth $11,078,000 as of its […] - 2025-08-15 05:17:09
Axsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $189.00 at Royal Bank Of Canada
Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its price objective increased by analysts at Royal Bank Of Canada from $184.00 to $189.00 in a research report issued on Tuesday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Royal Bank Of Canada’s price objective suggests a potential upside of 83.03% from the […] - 2025-08-07 05:30:53
KLP Kapitalforvaltning AS Decreases Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM)
KLP Kapitalforvaltning AS reduced its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 6.8% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 8,200 shares of the company’s stock after selling 600 shares during the period. KLP Kapitalforvaltning AS’s holdings in Axsome Therapeutics were worth […] - 2025-07-29 05:28:50
Cerity Partners LLC Raises Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM)
Cerity Partners LLC lifted its holdings in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 15.5% in the first quarter, HoldingsChannel.com reports. The institutional investor owned 5,707 shares of the company’s stock after purchasing an additional 766 shares during the period. Cerity Partners LLC’s holdings in Axsome Therapeutics were worth $666,000 as of […] - 2025-07-25 04:50:58
12,745 Shares in Axsome Therapeutics, Inc. (NASDAQ:AXSM) Acquired by Y Intercept Hong Kong Ltd
Y Intercept Hong Kong Ltd purchased a new stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) in the 1st quarter, HoldingsChannel.com reports. The fund purchased 12,745 shares of the company’s stock, valued at approximately $1,486,000. A number of other hedge funds have also recently made changes to their positions in AXSM. HighTower Advisors LLC […] - 2025-07-24 06:02:49
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Purchased by New York State Common Retirement Fund
New York State Common Retirement Fund raised its stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 49.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 33,581 shares of the company’s stock after buying an additional 11,090 […] - 2025-07-22 07:13:06
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Bought by Mutual of America Capital Management LLC
Mutual of America Capital Management LLC lifted its position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 0.3% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 39,623 shares of the company’s stock after acquiring an additional 136 […] - 2025-07-17 05:39:38
D.A. Davidson & CO. Has $788,000 Stock Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)
D.A. Davidson & CO. reduced its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 17.9% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 6,755 shares of the company’s stock after selling 1,475 shares during the quarter. D.A. Davidson […] - 2025-07-10 05:31:08
Head-To-Head Review: Axsome Therapeutics (NASDAQ:AXSM) vs. Rosetta Genomics (OTCMKTS:ROSGQ)
Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) and Rosetta Genomics (OTCMKTS:ROSGQ – Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, valuation, earnings, risk and dividends. Risk and Volatility Axsome Therapeutics has a beta […] - 2025-07-07 02:28:50
Janney Montgomery Scott LLC Has $1.74 Million Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM)
Janney Montgomery Scott LLC raised its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 8.6% in the 1st quarter, HoldingsChannel reports. The fund owned 14,923 shares of the company’s stock after buying an additional 1,178 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Axsome Therapeutics were worth $1,740,000 at the end […] - 2025-06-27 04:26:52
AXSM Makes Notable Cross Below Critical Moving Average
In trading on Monday, shares of Axsome Therapeutics Inc (Symbol: AXSM) crossed below their 200 day moving average of $102.28, changing hands as low as $101.01 per share. Axsome Therapeutics Inc shares are currently trading down about 1.9% on the day. The chart below shows the - 2025-06-16 12:41:26
GAMMA Investing LLC Increases Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM)
GAMMA Investing LLC increased its stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 38,571.9% during the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 22,043 shares of the company’s stock after buying an additional 21,986 shares during the quarter. GAMMA Investing […] - 2025-06-13 05:14:47
Rhumbline Advisers Grows Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)
Rhumbline Advisers boosted its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 6.9% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 54,760 shares of the company’s stock after acquiring an additional 3,515 shares during the quarter. Rhumbline Advisers’ holdings in Axsome Therapeutics […] - 2025-06-12 05:31:01
HC Wainwright Reiterates “Buy” Rating for Axsome Therapeutics (NASDAQ:AXSM)
Axsome Therapeutics (NASDAQ:AXSM – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They currently have a $180.00 target price on the stock. HC Wainwright’s price target would suggest a potential upside of 66.54% from the stock’s previous close. Several other […] - 2025-06-12 02:18:55
Needham & Company LLC Cuts Axsome Therapeutics (NASDAQ:AXSM) Price Target to $150.00
Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its price objective decreased by Needham & Company LLC from $153.00 to $150.00 in a note issued to investors on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Needham & Company LLC’s price target would suggest a potential upside of 36.48% from the […] - 2025-06-11 02:44:51
Nuveen Asset Management LLC Increases Stock Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM)
Nuveen Asset Management LLC raised its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 118.1% during the 4th quarter, HoldingsChannel.com reports. The firm owned 221,202 shares of the company’s stock after acquiring an additional 119,780 shares during the period. Nuveen Asset Management LLC’s holdings in Axsome Therapeutics were worth $18,716,000 as of its […] - 2025-05-25 06:03:20
Captrust Financial Advisors Sells 2,769 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)
Captrust Financial Advisors decreased its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 48.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 2,953 shares of the company’s stock after selling 2,769 shares during the period. Captrust Financial Advisors’ holdings in Axsome Therapeutics […] - 2025-05-22 04:47:00
Comerica Bank Sells 3,570 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)
Comerica Bank trimmed its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 32.6% during the 4th quarter, HoldingsChannel reports. The firm owned 7,374 shares of the company’s stock after selling 3,570 shares during the quarter. Comerica Bank’s holdings in Axsome Therapeutics were worth $624,000 at the end of the most recent reporting period. […] - 2025-05-15 04:52:49
Axsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $162.00
Axsome Therapeutics (NASDAQ:AXSM – Free Report) had its target price lifted by Robert W. Baird from $160.00 to $162.00 in a report released on Tuesday, Marketbeat reports. Robert W. Baird currently has an outperform rating on the stock. Other research analysts have also recently issued research reports about the company. HC Wainwright reaffirmed a “buy” […] - 2025-05-09 03:56:43
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Purchased by Price T Rowe Associates Inc. MD
Price T Rowe Associates Inc. MD raised its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 12.1% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 31,228 shares of the company’s stock after acquiring an additional 3,366 shares during the period. Price T Rowe Associates […] - 2025-05-07 05:50:49
Axsome Therapeutics (NASDAQ:AXSM) Trading Up 5.6% After Earnings Beat
Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report)’s stock price was up 5.6% during trading on Monday following a better than expected earnings announcement. The stock traded as high as $117.60 and last traded at $118.54. Approximately 231,459 shares changed hands during mid-day trading, a decline of 66% from the average daily volume of 683,737 […] - 2025-05-07 02:24:42
Legal & General Group Plc Decreases Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM)
Legal & General Group Plc cut its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 1.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 36,370 shares of the company’s stock after selling 503 shares during the period. Legal […] - 2025-04-24 05:06:51
Raymond James Financial Inc. Purchases New Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)
Raymond James Financial Inc. bought a new position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 174,586 shares of the company’s stock, valued at approximately $14,771,000. A number of […] - 2025-04-22 05:10:57
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Acquired by Summit Investment Advisors Inc.
Summit Investment Advisors Inc. boosted its position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 4.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,852 shares of the company’s stock after purchasing an additional 162 shares […] - 2025-04-21 04:56:55
Russell Investments Group Ltd. Boosts Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)
Russell Investments Group Ltd. boosted its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 1,815.0% in the fourth quarter, HoldingsChannel.com reports. The firm owned 19,437 shares of the company’s stock after buying an additional 18,422 shares during the quarter. Russell Investments Group Ltd.’s holdings in Axsome Therapeutics were worth $1,645,000 as of its […] - 2025-04-20 05:20:47
Jefferies Financial Group Initiates Coverage on Axsome Therapeutics (NASDAQ:AXSM)
Jefferies Financial Group started coverage on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a research report sent to investors on Monday morning, Marketbeat reports. The brokerage issued a buy rating and a $200.00 price objective on the stock. AXSM has been the topic of several other reports. William Blair reaffirmed an “outperform” rating […] - 2025-04-08 02:40:49
Schroder Investment Management Group Sells 34,158 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)
Schroder Investment Management Group decreased its stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 58.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,142 shares of the company’s stock after selling 34,158 shares during the quarter. Schroder […] - 2025-04-07 05:13:00
Brokerages Set Axsome Therapeutics, Inc. (NASDAQ:AXSM) PT at $167.64
Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report) have received an average rating of “Buy” from the fifteen analysts that are currently covering the company, Marketbeat reports. Fifteen equities research analysts have rated the stock with a buy recommendation. The average 12-month target price among brokers that have covered the stock in the […] - 2025-04-03 02:50:59
KLP Kapitalforvaltning AS Makes New $745,000 Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM)
KLP Kapitalforvaltning AS acquired a new stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 8,800 shares of the company’s stock, valued at approximately $745,000. Other institutional investors and hedge funds have […] - 2025-04-02 05:12:56

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.